Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Driving forces in cancer diagnostics.

Gander TR, Brody EN, Mehler RE, Heilig JS, Singer BS, Gold L.

MLO Med Lab Obs. 2003 Jan;35(1):10-6, 20; quiz 20-1. No abstract available. Erratum in: MLO Med Lab Obs. 2003 Apr;35(4):43.

PMID:
12561741
2.

Genomics. Medicine's future in our molecules.

Larson L.

Trustee. 2000 Jan;53(1):8-12, 1.

PMID:
11785218
3.

Proteomics: the next revolution in laboratory medicine?

Plebani M.

Clin Chim Acta. 2005 Jul 24;357(2):113-22. Review.

PMID:
15941565
4.

The changing landscape of HIV diagnostics.

Slev P.

MLO Med Lab Obs. 2012 Nov;44(11):8-10, 12, 14; quiz 16. No abstract available.

PMID:
23173518
5.

Criteria for tumor marker evaluation and utilization.

Fleisher M.

MLO Med Lab Obs. 2003 Apr;35(4):16-8; quiz 20-1. No abstract available.

PMID:
12705209
6.

From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma.

Daigo Y, Nakamura Y.

Gen Thorac Cardiovasc Surg. 2008 Feb;56(2):43-53. doi: 10.1007/s11748-007-0211-x. Review.

PMID:
18297458
7.

Serum tumor markers: part II--practical considerations and limitations of testing.

Hoefner DM.

MLO Med Lab Obs. 2006 Feb;38(2):10-1, 14-6; quiz 18-9.

PMID:
16583620
8.

Functional genomics: improving cancer prognosis and drug development.

Mariani SM.

MedGenMed. 2003 Mar 14;5(1):18. No abstract available.

9.

Cancer proteomics: Serum diagnostics for tumor marker discovery.

Rai AJ, Chan DW.

Ann N Y Acad Sci. 2004 Jun;1022:286-94. Review.

PMID:
15251974
10.
11.

The Human Genome Project: lessons from large-scale biology.

Collins FS, Morgan M, Patrinos A.

Science. 2003 Apr 11;300(5617):286-90. No abstract available.

PMID:
12690187
12.

Cancer procoagulant--CP.

Rucińska M, Gacko M, Skrzydlewski Z.

Rocz Akad Med Bialymst. 1997;42 Suppl 1:110-7. Review.

PMID:
9337529
13.

The future of clinical laboratory genomics.

Billings PR, Brown MP.

MLO Med Lab Obs. 2004 Dec;36(12):8-10, 12-5; quiz 16-7. Review. No abstract available.

PMID:
15648511
14.

Genomic microarrays in cancer molecular diagnostics: just biomarker discovery tools or future bedside clinical assays?

Ross JS.

Expert Rev Mol Diagn. 2005 Nov;5(6):837-8. No abstract available.

PMID:
16255622
15.

How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer.

Cordero OJ, De Chiara L, Lemos-González Y, Páez de la Cadena M, Rodríguez-Berrocal FJ.

Anticancer Res. 2008 Jul-Aug;28(4C):2333-41. Review.

16.

Continuing the 'ome' revolution.

Appasani K.

Drug Discov Today. 2002 Feb 1;7(3):176-8. No abstract available.

PMID:
11815232
17.

Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging.

Rutman AM, Kuo MD.

Eur J Radiol. 2009 May;70(2):232-41. doi: 10.1016/j.ejrad.2009.01.050. Review.

PMID:
19303233
18.

[Genomic project network and the patents (discussion)].

Hayashizaki Y, Oinuma T, Kohtsuki S.

Tanpakushitsu Kakusan Koso. 2004 Dec;49(17 Suppl):3001-16. Japanese. No abstract available.

PMID:
15669291
19.

Forensic bioinformatician aims to solve mysteries of biomarker studies.

Savage L.

J Natl Cancer Inst. 2008 Jul 16;100(14):983-7. doi: 10.1093/jnci/djn248. No abstract available.

20.

Evolving 'omics' technologies for diagnostics of head and neck cancer.

Nagaraj NS.

Brief Funct Genomic Proteomic. 2009 Jan;8(1):49-59. doi: 10.1093/bfgp/elp004. Review.

Items per page

Supplemental Content

Support Center